Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Cathinone or [[:Category:Biologics|Biologic]]

Use the filters below to narrow your results.

generic:
3-MMC (1) · Adalimumab (1) · Butylone (1) · Cathinone (1) · Ephylone (1) · Ethcathinone (1) · Ethylone (1) · Evolocumab (1) · Hexedrone (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Pentedrone (1)
brand:
None (14) · Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1) · Repatha (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)
uses:
None (15) · '"`UNIQ--vote-0000147C-QINU`"', '"`UNIQ--vote-0000147D-QINU`"', '"`UNIQ--vote-0000147E-QINU`"' (1)
starting dose:
None (14) · 140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume) (1) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1)
preparations:
None (14) · 140 mg/mL single-use prefilled syringe and SureClick autoinjector; Pushtronex 420 mg/3.5 mL on-body infusor (1) · 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1)
fda max:
None (14) · 40 mg every week (selected indications); otherwise 40 mg every other week (1) · 420 mg/month (1)
routes:
None (14) · Subcutaneous (2)
onset:
None (14) · LDL reduction ~50-60% from baseline at 1-2 weeks (1) · Symptomatic effect within weeks; full response by 12-24 weeks (1)
duration:
None (14) · 2 weeks per dose (1) · 2-4 weeks per dose (1)
halflife:
None (14) · ~11-17 days'"`UNIQ--ref-0000147F-QINU`"' (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1)
bioavailability:
None (14) · ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1) · ~72% from SC depot'"`UNIQ--ref-00001480-QINU`"' (1)
pregnancy:
None (15) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (15) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 16 results in range #1 to #16.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"